{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T17:25:43Z","timestamp":1783013143565,"version":"3.54.6"},"reference-count":109,"publisher":"Hindawi Limited","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":399,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Neurol Scand"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1111\/ane.12261","type":"journal-article","created":{"date-parts":[[2014,7,29]],"date-time":"2014-07-29T06:29:08Z","timestamp":1406615348000},"page":"211-221","source":"Crossref","is-referenced-by-count":26,"title":["Glucocorticoids in myasthenia gravis - if, when, how, and how much?"],"prefix":"10.1155","volume":"130","author":[{"given":"S.","family":"Hoffmann","sequence":"first","affiliation":[{"name":"Department of Neurology; Charite - Universit\u00e4tsmedizin; Berlin Germany"},{"name":"NeuroCure Clinical Research Center; Charite - Universit\u00e4tsmedizin; Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kohler","sequence":"additional","affiliation":[{"name":"Department of Neurology; Charite - Universit\u00e4tsmedizin; Berlin Germany"},{"name":"NeuroCure Clinical Research Center; Charite - Universit\u00e4tsmedizin; Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ziegler","sequence":"additional","affiliation":[{"name":"Department of Neurology; Charite - Universit\u00e4tsmedizin; Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Meisel","sequence":"additional","affiliation":[{"name":"Department of Neurology; Charite - Universit\u00e4tsmedizin; Berlin Germany"},{"name":"NeuroCure Clinical Research Center; Charite - Universit\u00e4tsmedizin; Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","published-online":{"date-parts":[[2014,7,29]]},"reference":[{"key":"10.1111\/ane.12261-BIB0001|ane12261-cit-0001","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1111\/ane.12261-BIB0002|ane12261-cit-0002","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1001\/jama.1957.02980130015004","article-title":"Chronic thyroiditis and autoimmunization","volume":"164","author":"Witebsky","year":"1957","journal-title":"J Am Med Assoc"},{"key":"10.1111\/ane.12261-BIB0003|ane12261-cit-0003","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1111\/ane.12261-BIB0004|ane12261-cit-0004","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/archneurol.2012.437","article-title":"Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis","volume":"69","author":"Jacob","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1111\/ane.12261-BIB0005|ane12261-cit-0005","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00415-011-6194-7","article-title":"Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis","volume":"259","author":"Pevzner","year":"2012","journal-title":"J Neurol"},{"key":"10.1111\/ane.12261-BIB0006|ane12261-cit-0006","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1196\/annals.1254.053","article-title":"The epidemiology of myasthenia gravis","volume":"998","author":"Phillips","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"10.1111\/ane.12261-BIB0007|ane12261-cit-0007","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1136\/jnnp.2008.144980","article-title":"Immunosuppressant drugs for myasthenia gravis","volume":"80","author":"Hart","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1111\/ane.12261-BIB0008|ane12261-cit-0008","first-page":"CD006986","article-title":"Acetylcholinesterase inhibitor treatment for myasthenia gravis","author":"Mehndiratta","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/ane.12261-BIB0009|ane12261-cit-0009","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1600-0404.1971.tb07501.x","article-title":"Myasthenia gravis and myasthenic syndromes treated with prednisone","volume":"47","author":"Kjaer","year":"1971","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/ane.12261-BIB0010|ane12261-cit-0010","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s004150050059","article-title":"Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients","volume":"244","author":"Beekman","year":"1997","journal-title":"J Neurol"},{"key":"10.1111\/ane.12261-BIB0011|ane12261-cit-0011","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/mus.1221","article-title":"Steroids have an important role","volume":"25","author":"Bedlack","year":"2002","journal-title":"Muscle Nerve"},{"key":"10.1111\/ane.12261-BIB0012|ane12261-cit-0012","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/mus.1220","article-title":"Steroids are overutilized","volume":"25","author":"Rivner","year":"2002","journal-title":"Muscle Nerve"},{"key":"10.1111\/ane.12261-BIB0013|ane12261-cit-0013","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.autrev.2010.11.009","article-title":"The kaleidoscope of glucorticoid effects on immune system","volume":"10","author":"Zen","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1111\/ane.12261-BIB0014|ane12261-cit-0014","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/ncprheum0898","article-title":"Genomic and nongenomic effects of glucocorticoids","volume":"4","author":"Stahn","year":"2008","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"Suppl 1","key":"10.1111\/ane.12261-BIB0015|ane12261-cit-0015","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1002\/ana.410370707","article-title":"Myasthenia gravis: immunological mechanisms and immunotherapy","volume":"37","author":"Lewis","year":"1995","journal-title":"Ann Neurol"},{"key":"10.1111\/ane.12261-BIB0016|ane12261-cit-0016","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1172\/JCI111757","article-title":"Effects of in vitro corticosteroids on b cell activation, proliferation, and differentiation","volume":"75","author":"Cupps","year":"1985","journal-title":"J Clin Invest"},{"key":"10.1111\/ane.12261-BIB0017|ane12261-cit-0017","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1212\/WNL.30.5.557","article-title":"Humoral immunity in myasthenia gravis: effect of steroids and thymectomy","volume":"30","author":"Tindall","year":"1980","journal-title":"Neurology"},{"key":"10.1111\/ane.12261-BIB0018|ane12261-cit-0018","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1056\/NEJM199406233302507","article-title":"Myasthenia gravis","volume":"330","author":"Drachman","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1111\/ane.12261-BIB0019|ane12261-cit-0019","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1172\/JCI29894","article-title":"Myasthenia gravis: past, present, and future","volume":"116","author":"Conti-Fine","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1111\/ane.12261-BIB0020|ane12261-cit-0020","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1002\/1521-4141(200007)30:7<1807::AID-IMMU1807>3.0.CO;2-N","article-title":"The effect of calcineurin inhibitors and corticosteroids on the differentiation of human dendritic cells","volume":"30","author":"Woltman","year":"2000","journal-title":"Eur J Immunol"},{"key":"10.1111\/ane.12261-BIB0021|ane12261-cit-0021","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/ni1254","article-title":"Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages","volume":"6","author":"Harrington","year":"2005","journal-title":"Nat Immunol"},{"key":"10.1111\/ane.12261-BIB0022|ane12261-cit-0022","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1600-065X.2008.00628.x","article-title":"Th17 cells in human disease","volume":"223","author":"Tesmer","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1111\/ane.12261-BIB0023|ane12261-cit-0023","doi-asserted-by":"crossref","first-page":"e826","DOI":"10.1111\/j.1365-2567.2009.03089.x","article-title":"Disequilibrium of T helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravis","volume":"128","author":"Mu","year":"2009","journal-title":"Immunology"},{"key":"10.1111\/ane.12261-BIB0024|ane12261-cit-0024","first-page":"540","article-title":"[Thymoma T helper type 17 cells and related cytokines in myasthenia gravis]","volume":"51","author":"Wang","year":"2012","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"10.1111\/ane.12261-BIB0025|ane12261-cit-0025","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1600-0404.2009.01158.x","article-title":"Effect of high-dose methylprednisolone treatment on Th17 cells in patients with multiple sclerosis in relapse","volume":"120","author":"Liu","year":"2009","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/ane.12261-BIB0026|ane12261-cit-0026","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood-2003-11-3900","article-title":"Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis","volume":"105","author":"Balandina","year":"2005","journal-title":"Blood"},{"key":"10.1111\/ane.12261-BIB0027|ane12261-cit-0027","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1001\/archneur.58.1.91","article-title":"High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes","volume":"58","author":"Leussink","year":"2001","journal-title":"Arch Neurol"},{"key":"10.1111\/ane.12261-BIB0028|ane12261-cit-0028","doi-asserted-by":"crossref","first-page":"8100","DOI":"10.1073\/pnas.87.20.8100","article-title":"Steroids induce acetylcholine receptors on cultured human muscle: implications for myasthenia gravis","volume":"87","author":"Kaplan","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1111\/ane.12261-BIB0029|ane12261-cit-0029","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0014-2999(79)90109-2","article-title":"The effect of prednisolone on neuromuscular transmission in the rat diaphragm","volume":"55","author":"Wilgenburg","year":"1979","journal-title":"Eur J Pharmacol"},{"key":"10.1111\/ane.12261-BIB0030|ane12261-cit-0030","first-page":"CD002828","article-title":"Corticosteroids for myasthenia gravis","author":"Schneider-Gold","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/ane.12261-BIB0031|ane12261-cit-0031","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1001\/archneur.1964.00460200010002","article-title":"Corticotropin in treatment of ocular myasthenia; a controlled clinical trial","volume":"11","author":"Mount","year":"1964","journal-title":"Arch Neurol"},{"key":"10.1111\/ane.12261-BIB0032|ane12261-cit-0032","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/j.1749-6632.1976.tb47718.x","article-title":"Alternate-day prednisone: preliminary report of a double-blind controlled study","volume":"274","author":"Howard","year":"1976","journal-title":"Ann N Y Acad Sci"},{"key":"10.1111\/ane.12261-BIB0033|ane12261-cit-0033","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1600-0404.1998.tb05968.x","article-title":"Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study","volume":"97","author":"Lindberg","year":"1998","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/ane.12261-BIB0034|ane12261-cit-0034","first-page":"612","article-title":"Effectiveness of steroid treatment in juvenile myasthenia gravis","volume":"36","author":"Zhang","year":"1998","journal-title":"Chinese J Pediatr"},{"key":"10.1111\/ane.12261-BIB0035|ane12261-cit-0035","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/s-2003-41139","article-title":"Basic principles of immunotherapy for neurologic diseases","volume":"23","author":"Hohlfeld","year":"2003","journal-title":"Semin Neurol"},{"issue":"Suppl 23","key":"10.1111\/ane.12261-BIB0036|ane12261-cit-0036","first-page":"21","article-title":"Myasthenia gravis. An analysis of 295 cases","volume":"42","author":"Simpson","year":"1966","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/ane.12261-BIB0037|ane12261-cit-0037","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1001\/jama.1935.02760230013004","article-title":"Myasthenia gravis - effect of treatment with anterior pituitary extract: preliminary report","volume":"104","author":"Simon","year":"1935","journal-title":"J Am Med Assoc"},{"key":"10.1111\/ane.12261-BIB0038|ane12261-cit-0038","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1749-6632.1971.tb30766.x","article-title":"The use of ACTH and corticosteroids in myasthenia gravis","volume":"183","author":"Genkins","year":"1971","journal-title":"Ann N Y Acad Sci"},{"key":"10.1111\/ane.12261-BIB0039|ane12261-cit-0039","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1001\/archneur.1985.04060110031011","article-title":"High-dose intravenous methylprednisolone in myasthenia gravis","volume":"42","author":"Arsura","year":"1985","journal-title":"Arch Neurol"},{"key":"10.1111\/ane.12261-BIB0040|ane12261-cit-0040","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ana.410150316","article-title":"Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients","volume":"15","author":"Pascuzzi","year":"1984","journal-title":"Ann Neurol"},{"key":"10.1111\/ane.12261-BIB0041|ane12261-cit-0041","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1212\/WNL.34.2.170","article-title":"Myasthenia gravis: prolonged treatment with steroids","volume":"34","author":"Sghirlanzoni","year":"1984","journal-title":"Neurology"},{"key":"10.1111\/ane.12261-BIB0042|ane12261-cit-0042","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1600-0404.1991.tb04899.x","article-title":"Effectiveness of steroid treatment in myasthenia gravis: a retrospective study","volume":"84","author":"Cosi","year":"1991","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/ane.12261-BIB0043|ane12261-cit-0043","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000116785","article-title":"Long-term results of corticosteroid therapy in patients with myasthenia gravis","volume":"32","author":"Evoli","year":"1992","journal-title":"Eur Neurol"},{"key":"10.1111\/ane.12261-BIB0044|ane12261-cit-0044","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11912-001-0024-5","article-title":"Acknowledgment of uncertainty: a fundamental means to ensure scientific and ethical validity in clinical research","volume":"3","author":"Djulbegovic","year":"2001","journal-title":"Curr Oncol Rep"},{"key":"10.1111\/ane.12261-BIB0045|ane12261-cit-0045","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1212\/WNL.1.3.145","article-title":"Clinical-evaluation of ACTH and cortisone in myasthenia gravis","volume":"1","author":"Millikan","year":"1951","journal-title":"Neurology"},{"key":"10.1111\/ane.12261-BIB0046|ane12261-cit-0046","first-page":"124","article-title":"Effect of adrenocorticotropic hormone (ACTH) and cortisone administration in patients with myasthenia gravis and report of onset of myasthenia gravis during prolonged cortisone administration","volume":"91","author":"Grob","year":"1952","journal-title":"Bull Johns Hopkins Hosp"},{"key":"10.1111\/ane.12261-BIB0047|ane12261-cit-0047","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jocn.2005.12.041","article-title":"Clinical predictors of steroid-induced exacerbation in myasthenia gravis","volume":"13","author":"Bae","year":"2006","journal-title":"J Clin Neurosci"},{"key":"10.1111\/ane.12261-BIB0048|ane12261-cit-0048","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1001\/archneur.1975.00490520054008","article-title":"Myasthenia gravis and acetylcholine receptor. Effect of steroids in clinical course and cellular immune response to acetylcholine receptor","volume":"32","author":"Abramsky","year":"1975","journal-title":"Arch Neurol"},{"key":"10.1111\/ane.12261-BIB0049|ane12261-cit-0049","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1084\/jem.132.6.1055","article-title":"Glucocorticoids and cellular immunity in vitro. Facilitation of the sensitization phase and inhibition of the effector phase of a lymphocyte anti-fibroblast reaction","volume":"132","author":"Cohen","year":"1970","journal-title":"J Exp Med"},{"key":"10.1111\/ane.12261-BIB0050|ane12261-cit-0050","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1056\/NEJM197401102900204","article-title":"Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment","volume":"290","author":"Seybold","year":"1974","journal-title":"N Engl J Med"},{"key":"10.1111\/ane.12261-BIB0051|ane12261-cit-0051","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1136\/jnnp.54.5.406","article-title":"Actuarial analysis of the occurrence of remissions following thymectomy for myasthenia gravis in 400 patients","volume":"54","author":"Durelli","year":"1991","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1111\/ane.12261-BIB0052|ane12261-cit-0052","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","article-title":"Guidelines for treatment of autoimmune neuromuscular transmission disorders","volume":"17","author":"Skeie","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1111\/ane.12261-BIB0053|ane12261-cit-0053","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1212\/WNL.41.6.919","article-title":"Factors influencing outcome of prednisone dose reduction in myasthenia gravis","volume":"41","author":"Miano","year":"1991","journal-title":"Neurology"},{"key":"10.1111\/ane.12261-BIB0054|ane12261-cit-0054","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1212\/01.wnl.0000312373.67493.7f","article-title":"A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis","volume":"71","year":"2008","journal-title":"Neurology"},{"key":"10.1111\/ane.12261-BIB0055|ane12261-cit-0055","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","article-title":"An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis","volume":"71","author":"Sanders","year":"2008","journal-title":"Neurology"},{"key":"10.1111\/ane.12261-BIB0056|ane12261-cit-0056","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1136\/jnnp-2011-300148","article-title":"Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis","volume":"82","author":"Yoshikawa","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1111\/ane.12261-BIB0057|ane12261-cit-0057","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1212\/01.wnl.0000263481.14289.90","article-title":"Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the quality standards subcommittee of the American academy of neurology","volume":"68","author":"Benatar","year":"2007","journal-title":"Neurology"},{"key":"10.1111\/ane.12261-BIB0058|ane12261-cit-0058","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1600-0404.1988.tb06970.x","article-title":"Ocular myasthenia: diagnostic and therapeutic problems","volume":"77","author":"Evoli","year":"1988","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/ane.12261-BIB0059|ane12261-cit-0059","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1749-6632.1976.tb47723.x","article-title":"Oral corticosteroids in the treatment of ocular myasthenia gravis","volume":"274","author":"Fischer","year":"1976","journal-title":"Ann N Y Acad Sci"},{"key":"10.1111\/ane.12261-BIB0060|ane12261-cit-0060","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0022-5223(96)70264-7","article-title":"Delayed remission after thymectomy for myasthenia gravis of the purely ocular type","volume":"112","author":"Nakamura","year":"1996","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1111\/ane.12261-BIB0061|ane12261-cit-0061","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/jnnp.62.2.156","article-title":"Ocular myasthenia gravis: response to long-term immunosuppressive treatment","volume":"62","author":"Sommer","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1111\/ane.12261-BIB0062|ane12261-cit-0062","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1212\/01.wnl.0000327669.75695.38","article-title":"Treatment of ocular symptoms in myasthenia gravis","volume":"71","author":"Bhanushali","year":"2008","journal-title":"Neurology"},{"key":"10.1111\/ane.12261-BIB0063|ane12261-cit-0063","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/WNO.0b013e3182536558","article-title":"Safety of prednisone for ocular myasthenia gravis","volume":"32","author":"Bruce","year":"2012","journal-title":"J Neuroophthalmol"},{"key":"10.1111\/ane.12261-BIB0064|ane12261-cit-0064","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1001\/archneur.1996.00550080128020","article-title":"Beneficial effects of corticosteroids on ocular myasthenia gravis","volume":"53","author":"Kupersmith","year":"1996","journal-title":"Arch Neurol"},{"key":"10.1111\/ane.12261-BIB0065|ane12261-cit-0065","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1749-6632.1998.tb10937.x","article-title":"Acetylcholine receptor epitopes in ocular myasthenia","volume":"841","author":"Kaminski","year":"1998","journal-title":"Ann N Y Acad Sci"},{"key":"10.1111\/ane.12261-BIB0066|ane12261-cit-0066","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/archneur.60.2.243","article-title":"Development of generalized disease at 2\u00a0years in patients with ocular myasthenia gravis","volume":"60","author":"Kupersmith","year":"2003","journal-title":"Arch Neurol"},{"key":"10.1111\/ane.12261-BIB0067|ane12261-cit-0067","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00041327-200312000-00002","article-title":"Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis","volume":"23","author":"Mee","year":"2003","journal-title":"J Neuroophthalmol"},{"key":"10.1111\/ane.12261-BIB0068|ane12261-cit-0068","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/mus.21555","article-title":"Ocular myasthenia gravis in a senior population: diagnosis, therapy, and prognosis","volume":"41","author":"Allen","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1111\/ane.12261-BIB0069|ane12261-cit-0069","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1001\/archneur.57.5.750","article-title":"Treatment of ocular myasthenia with corticosteroids: yes","volume":"57","author":"Agius","year":"2000","journal-title":"Arch Neurol"},{"key":"10.1111\/ane.12261-BIB0070|ane12261-cit-0070","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0960-8966(00)00173-5","article-title":"Therapeutic options in ocular myasthenia gravis","volume":"11","author":"Evoli","year":"2001","journal-title":"Neuromuscul Disord"},{"key":"10.1111\/ane.12261-BIB0071|ane12261-cit-0071","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1212\/WNL.55.1.7","article-title":"Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the quality standards subcommittee of the American academy of neurology","volume":"55","author":"Gronseth","year":"2000","journal-title":"Neurology"},{"key":"10.1111\/ane.12261-BIB0072|ane12261-cit-0072","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1072-7515(01)00795-5","article-title":"Analysis of thymectomy for myasthenia gravis in older patients: a 20-year single institution experience","volume":"192","author":"Abt","year":"2001","journal-title":"J Am Coll Surg"},{"key":"10.1111\/ane.12261-BIB0073|ane12261-cit-0073","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0003-4975(96)00376-1","article-title":"Extended thymectomy for myasthenia gravis patients: a 20-year review","volume":"62","author":"Masaoka","year":"1996","journal-title":"Ann Thorac Surg"},{"key":"10.1111\/ane.12261-BIB0074|ane12261-cit-0074","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0022-510X(03)00087-X","article-title":"Video-assisted thoracoscopic extended thymectomy and extended transsternal thymectomy (t-3b) in non-thymomatous myasthenia gravis patients: remission after 6\u00a0years of follow-up","volume":"212","author":"Mantegazza","year":"2003","journal-title":"J Neurol Sci"},{"key":"10.1111\/ane.12261-BIB0075|ane12261-cit-0075","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000050800","article-title":"Prognostic factors of thymectomy in patients with myasthenia gravis: a cohort of 132 patients","volume":"46","author":"Tellez-Zenteno","year":"2001","journal-title":"Eur Neurol"},{"key":"10.1111\/ane.12261-BIB0076|ane12261-cit-0076","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0003-4975(10)66861-0","article-title":"Thymectomy for myasthenia gravis: recent observations and comparisons with past experience","volume":"48","author":"Mulder","year":"1989","journal-title":"Ann Thorac Surg"},{"key":"10.1111\/ane.12261-BIB0077|ane12261-cit-0077","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/BF02470579","article-title":"Favorable results of thymectomy combined with prednisolone alternate-day administration in myasthenia gravis","volume":"17","author":"Yamaguchi","year":"1987","journal-title":"Jpn J Surg"},{"key":"10.1111\/ane.12261-BIB0078|ane12261-cit-0078","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.ejcts.2006.03.022","article-title":"Does perioperative high-dose prednisolone have clinical benefits for generalized myasthenia gravis?","volume":"29","author":"Sekine","year":"2006","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1111\/ane.12261-BIB0079|ane12261-cit-0079","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s11748-007-0195-6","article-title":"Preoperative steroid therapy stabilizes postoperative respiratory conditions in myasthenia gravis","volume":"56","author":"Kaneda","year":"2008","journal-title":"Gen Thorac Cardiovasc Surg"},{"key":"10.1111\/ane.12261-BIB0080|ane12261-cit-0080","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.athoracsur.2003.10.039","article-title":"Experience with programmed steroid treatment with thymectomy in nonthymomatous myasthenia gravis","volume":"77","author":"Endo","year":"2004","journal-title":"Ann Thorac Surg"},{"key":"10.1111\/ane.12261-BIB0081|ane12261-cit-0081","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ejcts.2006.06.009","article-title":"Complete stable remission after extended transsternal thymectomy in myasthenia gravis","volume":"30","author":"Park","year":"2006","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1111\/ane.12261-BIB0082|ane12261-cit-0082","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.athoracsur.2009.07.036","article-title":"Modified maximal thymectomy for myasthenia gravis: effect of maximal resection on late neurologic outcome and predictors of disease remission","volume":"88","author":"Prokakis","year":"2009","journal-title":"Ann Thorac Surg"},{"key":"10.1111\/ane.12261-BIB0083|ane12261-cit-0083","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1007\/s005950050231","article-title":"Postoperative infection after transsternal thymectomy for myasthenia gravis: a retrospective analysis of 125 cases","volume":"28","author":"Machens","year":"1998","journal-title":"Surg Today"},{"key":"10.1111\/ane.12261-BIB0084|ane12261-cit-0084","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ejcts.2004.01.037","article-title":"Safety for preoperative use of steroids for transsternal thymectomy in myasthenia gravis","volume":"26","author":"Zielinski","year":"2004","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1111\/ane.12261-BIB0085|ane12261-cit-0085","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1212\/WNL.52.3.447","article-title":"Course and treatment of myasthenia gravis during pregnancy","volume":"52","author":"Batocchi","year":"1999","journal-title":"Neurology"},{"key":"10.1111\/ane.12261-BIB0086|ane12261-cit-0086","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/mus.20661","article-title":"Neuromuscular disorders in pregnancy","volume":"34","author":"Sax","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1111\/ane.12261-BIB0087|ane12261-cit-0087","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1055\/s-2004-829590","article-title":"The management of myasthenia gravis in pregnancy","volume":"24","author":"Ciafaloni","year":"2004","journal-title":"Semin Neurol"},{"key":"10.1111\/ane.12261-BIB0088|ane12261-cit-0088","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0301-2115(02)00051-9","article-title":"Myasthenia gravis in pregnancy: report on 69 cases","volume":"104","author":"Djelmis","year":"2002","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1111\/ane.12261-BIB0089|ane12261-cit-0089","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nrrheum.2009.103","article-title":"Management of RA medications in pregnant patients","volume":"5","author":"Ostensen","year":"2009","journal-title":"Nat Rev Rheumatol"},{"key":"10.1111\/ane.12261-BIB0090|ane12261-cit-0090","first-page":"97","article-title":"Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation","volume":"15","author":"Armenti","year":"2001","journal-title":"Clin Transpl"},{"key":"10.1111\/ane.12261-BIB0091|ane12261-cit-0091","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/ar3227","article-title":"Managing pregnancy in inflammatory rheumatological diseases","volume":"13","author":"Jain","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1111\/ane.12261-BIB0092|ane12261-cit-0092","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/tera.1420510107","article-title":"Teratogenic potential of corticosteroids in humans","volume":"51","author":"Fraser","year":"1995","journal-title":"Teratology"},{"key":"10.1111\/ane.12261-BIB0093|ane12261-cit-0093","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ajog.2007.05.046","article-title":"Maternal corticosteroid use and orofacial clefts","volume":"197","author":"Carmichael","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"10.1111\/ane.12261-BIB0094|ane12261-cit-0094","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/art.24003","article-title":"Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide prospective study","volume":"59","author":"Man","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1111\/ane.12261-BIB0095|ane12261-cit-0095","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1542\/peds.93.1.137","article-title":"American Academy of Pediatrics Committee on Drugs. The transfer of drugs and other chemicals into human milk","volume":"93","year":"1994","journal-title":"Pediatrics"},{"key":"10.1111\/ane.12261-BIB0096|ane12261-cit-0096","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/0002-9378(92)91596-3","article-title":"Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment","volume":"166","author":"Cowchock","year":"1992","journal-title":"Am J Obstet Gynecol"},{"key":"10.1111\/ane.12261-BIB0097|ane12261-cit-0097","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/01.grf.0000153206.85996.07","article-title":"Myasthenia gravis and pregnancy","volume":"48","author":"Stafford","year":"2005","journal-title":"Clin Obstet Gynecol"},{"key":"10.1111\/ane.12261-BIB0098|ane12261-cit-0098","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/ard.2005.038638","article-title":"Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data","volume":"65","author":"Silva","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/ane.12261-BIB0099|ane12261-cit-0099","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1749-6632.1987.tb51320.x","article-title":"The course of myasthenia gravis in patients treated with corticosteroids, azathioprine, and plasmapheresis","volume":"505","author":"Cornelio","year":"1987","journal-title":"Ann N Y Acad Sci"},{"key":"10.1111\/ane.12261-BIB0100|ane12261-cit-0100","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/j.1468-1331.2006.01382.x","article-title":"Safety of long-term combined immunosuppressive treatment in myasthenia gravis-analysis of adverse effects of 163 patients","volume":"13","author":"Rozsa","year":"2006","journal-title":"Eur J Neurol"},{"key":"10.1111\/ane.12261-BIB0101|ane12261-cit-0101","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1749-6632.1976.tb47717.x","article-title":"Corticotropin and corticosteroids in generalized myasthenia gravis: comparative studies and role in management","volume":"274","author":"Brunner","year":"1976","journal-title":"Ann N Y Acad Sci"},{"key":"10.1111\/ane.12261-BIB0102|ane12261-cit-0102","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1136\/ard.2008.092163","article-title":"Dose-related patterns of glucocorticoid-induced side effects","volume":"68","author":"Huscher","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/ane.12261-BIB0103|ane12261-cit-0103","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1749-6632.1981.tb33767.x","article-title":"Effect of immunosuppressive drugs (azathioprine)","volume":"377","author":"Mertens","year":"1981","journal-title":"Ann N Y Acad Sci"},{"key":"10.1111\/ane.12261-BIB0104|ane12261-cit-0104","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia gravis study group","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology"},{"key":"10.1111\/ane.12261-BIB0105|ane12261-cit-0105","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/mus.22212","article-title":"Cost analysis of myasthenia gravis from a large U.S. insurance database","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1111\/ane.12261-BIB0106|ane12261-cit-0106","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1196\/annals.1405.036","article-title":"Treatment and clinical research in myasthenia gravis: how far have we come?","volume":"1132","author":"Barohn","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1111\/ane.12261-BIB0107|ane12261-cit-0107","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta11070","article-title":"Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis","volume":"11","author":"Kanis","year":"2007","journal-title":"Health Technol Assess"},{"key":"10.1111\/ane.12261-BIB0108|ane12261-cit-0108","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.rmed.2009.01.003","article-title":"The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use","volume":"103","author":"Manson","year":"2009","journal-title":"Respir Med"},{"key":"10.1111\/ane.12261-BIB0109|ane12261-cit-0109","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.intimp.2005.11.002","article-title":"Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases","volume":"6","author":"Daoud","year":"2006","journal-title":"Int Immunopharmacol"}],"container-title":["Acta Neurologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fane.12261","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ane.12261\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T12:47:30Z","timestamp":1671540450000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ane.12261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,29]]},"references-count":109,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,10]]}},"URL":"https:\/\/doi.org\/10.1111\/ane.12261","relation":{},"ISSN":["0001-6314"],"issn-type":[{"value":"0001-6314","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7,29]]}}}